Literature DB >> 32843170

Compliance in subcutaneous and sublingual allergen immunotherapy: A nationwide study.

Morten Borg1, Anders Løkke2, Ole Hilberg2.   

Abstract

INTRODUCTION: Allergic rhino-conjunctivitis is a highly prevalent condition. In moderate to severe cases, allergen immunotherapy (AIT) is a cost-effective therapeutic option. Previous data have reported a large difference in treatment compliance of subcutaneously (SCIT) and sublingually (SLIT) administered AIT.
METHODS: By use of the unique civil registration number assigned to all Danish citizens and the Danish National Health Service Prescription Database, compliance rates of all patients prescribed with grass pollen AIT from January 1998 until December 2016 were analysed annually during the three-year treatment period.
RESULTS: The male/female ratio was close to 1:1 in SCIT, while SLIT was more frequently used by men. A large proportion of users was children or adolescents (32% and 45%, SCIT and SLIT, respectively). Compliance of both subcutaneous and sublingual treatment gradually fell each year; compliance in year 3 was 57% and 53% for subcutaneous and sublingual treatment, respectively. Compliance of grass pollen sublingual treatment was also analysed each year after registration on the Danish market. Compliance significantly increased following the introduction and stabilised on a relatively high level.
CONCLUSION: Based on previous studies, we hypothesised that AIT compliance would be low, especially in SLIT. However, in Denmark, compliance in SCIT and SLIT was almost similar, and the majority of patients completed the three-year treatment period with a compliance in the last quintile.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Allergen immunotherapy; Allergic rhino conjunctivitis; Compliance; Grass pollen allergy; Subcutaneous immunotherapy; Sublingual immunotherapy

Mesh:

Year:  2020        PMID: 32843170     DOI: 10.1016/j.rmed.2020.106039

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  4 in total

1.  Predictive Response to Immunotherapy Score: A Useful Tool for Identifying Eligible Patients for Allergen Immunotherapy.

Authors:  Ilaria Mormile; Francescopaolo Granata; Aikaterini Detoraki; Daniela Pacella; Francesca Della Casa; Felicia De Rosa; Antonio Romano; Amato de Paulis; Francesca Wanda Rossi
Journal:  Biomedicines       Date:  2022-04-22

Review 2.  Allergic Rhinitis: What Do We Know About Allergen-Specific Immunotherapy?

Authors:  Tadech Boonpiyathad; Mongkol Lao-Araya; Chirawat Chiewchalermsri; Sasipa Sangkanjanavanich; Hideaki Morita
Journal:  Front Allergy       Date:  2021-10-28

3.  Real-life adherence to subcutaneous immunotherapy: What has changed in the era of the COVID-19 pandemic.

Authors:  Ilkay Koca Kalkan; Hale Ates; Kurtulus Aksu; Selma Yesilkaya; Musa Topel; Dilek Cuhadar Ercelebi; Suleyman Turkyilmaz; Ali Oncul; Senay Demir
Journal:  World Allergy Organ J       Date:  2021-06-08       Impact factor: 4.084

4.  Sublingual immunotherapy tablet: a cost-minimizing alternative in the treatment of tree pollen-induced seasonal allergic rhinitis in Canada.

Authors:  Anne K Ellis; Rémi Gagnon; Eva Hammerby; Julia Shen; Sheena Gosain
Journal:  Allergy Asthma Clin Immunol       Date:  2021-07-08       Impact factor: 3.406

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.